Last10K.com

Allena Pharmaceuticals, Inc. (ALNA) SEC Filing 8-K Material Event for the period ending Monday, August 29, 2022

Allena Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1624658 Ticker: ALNA

View differences made from one to another to evaluate Allena Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allena Pharmaceuticals, Inc..

Continue

Assess how Allena Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Allena Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information
Ticker: ALNA
CIK: 1624658
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-237990
Submitted to the SEC: Fri Sep 02 2022 5:15:37 PM EST
Accepted by the SEC: Fri Sep 02 2022
Period: Monday, August 29, 2022
Industry: Biological Products No Disgnostic Substances
Events:
  1. Bankruptcy or Receivership
  2. Ending Agreement
  3. Event for Officers
  4. Listing Status

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/alna/0001193125-22-237990.htm